First Time Loading...

Arcus Biosciences Inc
NYSE:RCUS

Watchlist Manager
Arcus Biosciences Inc Logo
Arcus Biosciences Inc
NYSE:RCUS
Watchlist
Price: 17.77 USD 3.86%
Updated: May 15, 2024

Operating Margin
Arcus Biosciences Inc

-105.5%
Current
-193%
Average
-8.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-105.5%
=
Operating Profit
-250m
/
Revenue
237m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Arcus Biosciences Inc
NYSE:RCUS
1.6B USD
-105%
US
Abbvie Inc
NYSE:ABBV
287.8B USD
30%
US
Amgen Inc
NASDAQ:AMGN
169.8B USD
24%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.9B USD
39%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
107.4B USD
30%
AU
CSL Ltd
ASX:CSL
136.7B AUD
26%
US
Gilead Sciences Inc
NASDAQ:GILD
84B USD
32%
US
Moderna Inc
NASDAQ:MRNA
48B USD
-100%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
US
Biogen Inc
NASDAQ:BIIB
33.8B USD
22%
KR
Celltrion Inc
KRX:068270
39.6T KRW
30%
Arcus Biosciences Inc
NYSE:RCUS
Country US
Market Cap 1.6B USD
Operating Margin
-105%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 287.8B USD
Operating Margin
30%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 169.8B USD
Operating Margin
24%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 111.9B USD
Operating Margin
39%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 107.4B USD
Operating Margin
30%
CSL Ltd
ASX:CSL
Country AU
Market Cap 136.7B AUD
Operating Margin
26%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 84B USD
Operating Margin
32%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 48B USD
Operating Margin
-100%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
Operating Margin
-33%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 33.8B USD
Operating Margin
22%
Celltrion Inc
KRX:068270
Country KR
Market Cap 39.6T KRW
Operating Margin
30%

Profitability Report

View the profitability report to see the full profitability analysis for Arcus Biosciences Inc.

Full Profitability Report

See Also

Summary
RCUS intrinsic value, competitors valuation, and company profile.
DCF Valuation
RCUS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RCUS stock valuation using valuation multiples.
Wall Street Estimates
RCUS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RCUS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-105.5%
=
Operating Profit
-250m
/
Revenue
237m
What is the Operating Margin of Arcus Biosciences Inc?

Based on Arcus Biosciences Inc's most recent financial statements, the company has Operating Margin of -105.5%.

ALPHA SPREAD
Join more than 137,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.